Last updated: April 23, 2026
Who Supplies Prednisolone Acetate (API and Finished Drug Products)?
Prednisolone acetate is a long-established corticosteroid used in ophthalmic and other anti-inflammatory formulations. Supplier selection depends on whether the need is API (active pharmaceutical ingredient), finished dosage forms (notably eye drops/ophthalmic suspensions), or CMO/CDMO support for manufacturing, fill-finish, and packaging.
What Supplier Types Exist for Prednisolone Acetate?
1) API suppliers (prednisolone acetate bulk material)
Common supplier classes include:
- API manufacturers (generic and specialty chemical producers)
- Traders/distributors (sourcing from API plants)
- Licensors and contract chemical manufacturers (for custom sourcing and grade matching)
Typical procurement for API focuses on:
- Physical/chemical specs (identity, assay, impurities)
- Particle and form (where relevant to formulation performance)
- Regulatory status (DMF/CEP/USDMF where applicable for the target market)
2) Finished-dose suppliers (ophthalmic suspensions/eye drops)
For prednisolone acetate, most commercial demand is ophthalmic (often “prednisolone acetate ophthalmic suspension” products). Finished-dose supply comes from:
- Brand and generic finished-product manufacturers
- Ophthalmic formulation specialists
- Regional manufacturers supplying local markets
Selection focuses on:
- Concentration and presentation (commonly 0.12% or similar ophthalmic strengths, depending on region)
- Container system (bottles, droppers, preservative systems)
- GxP manufacturing and regulatory track record
3) CDMO/CMO partners (manufacture + fill-finish)
Where companies do not want to own manufacturing, prednisolone acetate formulations can be supported via:
- Ophthalmic suspension CDMOs with fill-finish capability
- General pharmaceutical CDMOs with suspension capability and regulatory documentation support
Selection focuses on:
- Ophthalmic manufacturing capability (sterility assurance, container compatibility)
- Batch release and documentation (quality systems, validation packages)
- Regulatory support (DMF/IND/ANDA readiness depending on pathway)
Which Companies Commonly Supply Prednisolone Acetate?
API and bulk material supply
Prednisolone acetate API is widely available through multiple market channels, typically including:
- Generics API producers
- Specialty chemical API manufacturers
- Regional API distributors
However, without confirmed, up-to-date sourcing lists for specific jurisdictions and grades, there is no defensible way to name “the” suppliers for prednisolone acetate that would stand up for procurement, audit, or regulatory due diligence.
Finished-dose and ophthalmic supply
Similarly, finished ophthalmic prednisolone acetate is sold by multiple companies across markets, but supplier identification must be tied to:
- Country/market
- Strength and dosage form
- Bottle/pack type and preservative system
- Regulatory listing status
Without market and product specifics, any supplier list risks being inaccurate for the intended procurement channel.
What Matters Most for Supplier Qualification (Procurement-Ready Checklist)
API qualification criteria
Core qualification inputs typically required by quality teams:
- Identity, assay, and impurity profile
- Stability and re-test period
- CoA traceability (lot-level)
- DMF or regulatory linkage (if filing support is needed)
- Compliance history (FDA/EU inspection outcomes, if relevant to the target market)
Finished-dose qualification criteria
For ophthalmic suspensions:
- Sterility and preservative strategy (per product design)
- Particle-size and suspension performance (caking and resuspendability)
- Container closure compatibility
- Shelf-life and in-use stability
- GMP manufacturing site suitability for the target market filing pathway
CDMO qualification criteria
For partners producing and filling:
- Ophthalmic suspension experience
- Validated aseptic/non-aseptic strategy (as applicable)
- Batch record and validation documentation availability
- Quality agreement terms (change control, deviations, CAPA ownership)
- Supply continuity (capacity, lead times, dual-sourcing strategy)
How to Decide Between API Sourcing vs Finished-Dose Sourcing
- If the goal is formulation ownership (e.g., ANDA/bridging strategy), procurement typically centers on API qualification plus formulation and fill-finish.
- If the goal is commercial launch or supply continuity, procurement typically centers on finished-dose sourcing with packaging and regulatory compliance aligned to the target market.
Key Takeaways
- Prednisolone acetate sourcing breaks into API, finished ophthalmic product, and CDMO fill-finish categories.
- Supplier identification must be tied to market, dosage form, and grade/strength to be procurement-accurate.
- Qualification should prioritize impurity/assay specs, regulatory documentation (DMF/CEP where applicable), and ophthalmic quality attributes (suspension performance, container compatibility, stability).
FAQs
-
Is prednisolone acetate supply primarily ophthalmic?
Prednisolone acetate demand is heavily weighted toward ophthalmic anti-inflammatory use, which drives much of the finished-dose and formulation supply chain.
-
Should procurement start with API or finished-dose?
Start with API when you own formulation and regulatory strategy; start with finished-dose when speed-to-supply and packaging compliance matter most.
-
What regulatory documentation typically matters for API prednisolone acetate?
API typically requires identity/assay/impurity control plus submission-support documentation such as DMF linkage where applicable.
-
What quality attributes matter most for ophthalmic suspensions?
Suspension performance, particle characteristics, container closure compatibility, stability, and in-use behavior.
-
Can CDMOs support prednisolone acetate suspension manufacturing and fill-finish?
Yes, where the CDMO has ophthalmic suspension capability and validated fill-finish and quality systems aligned with your filing pathway.
Sources
[1] FDA. Drug Development and Drug Interactions: DMF Information. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-master-files-and-drug-device-master-files
[2] European Medicines Agency (EMA). CEP and Certificates: Certificates of Suitability. EMA. https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/cep-certificates-suitability
[3] ICH. Q3A(R2), Q3B(R2), Q7, Q8, Q9, Q10 Quality Guidelines. International Council for Harmonisation. https://www.ich.org/page/quality-guidelines
